TailorCare has announced the purchase of the advanced computer vision-enabled patient monitoring platform developed by Stabl, a leading healthcare software company. Financial terms of the deal were not disclosed.
Stabl is a leading healthcare software company that has developed an advanced computer vision-enabled patient monitoring platform. Its proprietary technology enables real-time form-tracking to help patients perform exercises safely and effectively from the comfort of their homes without the need for wearable sensors. This technology is especially valuable for patients in between clinical visits or engaging in recovery independently, providing personalized feedback and intelligent engagement opportunities that ensure the patient is on the right path to recovery.
TailorCare is a risk-based care navigation company that takes a data-driven approach to improving patient outcomes for joint, back and muscle conditions. By combining a patient’s clinical assessment, health history, preferences and goals with predictive data and the latest evidence-based guidelines, the company helps patients choose and navigate the most effective treatment pathway. Its care navigation services include clinical assessments, patient education, provider matching and ongoing communication.
This transaction follows TailorCare’s December 2024 acquisition of RecoveryOne, a recovery-focused virtual physical therapy solution for employers, partners and health plans. RecoveryOne is headquartered in Walnut Creek, California.
“This addition to our self-care offering builds upon our acquisition of RecoveryOne, and represents a major step forward in our journey to build an industry-leading, integrated platform to support patients navigating and managing their MSK conditions,” said Rachel Winokur, founder and CEO of TailorCare.
According to data captured in the LevinPro HC database, this transaction represents the 221st eHealth acquisition of 2025, and the 22nd in the remote patient monitoring (RPM) specialty. There were 24 RPM transactions reported in 2024, and 22 in 2023.
